Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Clinical trial NCT06942234 · RECRUITING

Trial details

NCT number: NCT06942234
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Inoperable Locally Advanced HER2-Negative Breast Cancer Metastatic HER2-Negative Breast Cancer

Start date: 2025-06-01
Primary completion: 2027-06-30
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.